Eribulin ORA: A novel oral formulation of eribulin based on combination with the P-gp inhibitor HM30181A.

艾瑞布林 医学 紫杉醇 紫杉烷 药理学 转移性乳腺癌 乳腺癌 癌症 内科学 癌症研究
作者
Laura Pitzonka,Murray J. Cutler,Johnson Yiu‐Nam Lau,David L. Cutler,Rudolf Kwan,Michael Smolinski
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (15_suppl): e12577-e12577 被引量:2
标识
DOI:10.1200/jco.2019.37.15_suppl.e12577
摘要

e12577 Background: Eribulin is a potent synthetic derivative of the marine sponge natural product Halichondrin B that uniquely targets microtubule growth to induce apoptotic cell death. Eribulin is currently administered intravenously (IV) to treat patients with breast cancer and liposarcoma refractory to taxane therapy due to its superior efficacy in taxane resistant tumor types. Methods: Utilizing a proprietary Orascovery platform, Eribulin ORA, a novel orally-administered eribulin formulation has been developed, which combines the P-glycoprotein (P-gp) inhibitor, HM30181A, with oral eribulin. Results: HM30181A significantly improves the systemic exposure of oral eribulin in rodents, which enables remarkable tumor regression in murine xenografts. HM30181A improves eribulin plasma exposure > 5-fold in mouse model (AUC 0-24hr = 8224 ng*hr/mL with HM30181A vs. 1516 ng*hr/mL without HM30181A) and also improves eribulin oral bioavailability in the rat (%F = 35.0 with HM30181A vs. 16.1 without HM30181A). In vitro cell viability assays of MCF-7 and MDA-MB-231 breast cancer cell lines show eribulin is synergistic with other microtubule disrupting agents, including common first-line breast cancer therapy paclitaxel. In mice bearing orthotopic MDA-MB-231 breast tumor xenografts, oral eribulin with HM30181A was administered at eribulin doses of 0.5, 1.0, and 1.5 mg/kg Q2Dx3 (M,W,F)/week for four weeks. Only mice treated with 1.5 mg/kg (highest dose) eribulin had weight loss during treatment, with the observed weight loss was < 10%, (except for one mouse). All eribulin doses tested induced tumor regression, with 7/9 tumors in the 1.5 mg/kg eribulin group experiencing durable complete regression until study end, two-weeks post administration. Of the tumors in the Eribulin ORA-treated groups that resumed growth after treatment, the degree of tumor growth was minimal. Overall, Eribulin ORA was well tolerated and showed potent efficacy against breast cancer tumors, exhibiting nearly 100% growth inhibition at all dose levels tested. Conclusions: Eribulin ORA showed good oral absorption, efficacious systemic exposure, and importantly, excellent anti-cancer activity in a breast cancer model. In vitro studies demonstrated the synergistic potential of eribulin in combination with paclitaxel. Accordingly, the combination of Eribulin ORA with Oraxol (oral paclitaxel that has shown promising clinical data) may represent an excellent metronomic oral combination chemotherapy that warrants further investigation for patients with advanced breast cancer.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Yolo完成签到,获得积分10
刚刚
CY发布了新的文献求助10
刚刚
周稅完成签到,获得积分10
刚刚
迅速金鱼发布了新的文献求助10
刚刚
清秀龙猫完成签到 ,获得积分10
1秒前
1秒前
1秒前
mrx发布了新的文献求助10
1秒前
1秒前
2秒前
范范完成签到,获得积分10
2秒前
飞天817发布了新的文献求助10
2秒前
小鲤鱼吃大菠萝完成签到,获得积分10
2秒前
3秒前
guoless完成签到,获得积分10
3秒前
3秒前
sos发布了新的文献求助10
4秒前
4秒前
JinlongFan完成签到 ,获得积分10
4秒前
4秒前
帅气西牛发布了新的文献求助10
4秒前
清秀寄风发布了新的文献求助10
5秒前
超帅连虎完成签到,获得积分10
5秒前
陈琳发布了新的文献求助10
5秒前
文欣妍发布了新的文献求助10
6秒前
疯狂的青亦完成签到,获得积分10
7秒前
李健的小迷弟应助缪甲烷采纳,获得10
7秒前
超帅连虎发布了新的文献求助10
8秒前
8秒前
852应助jingwenli21采纳,获得10
8秒前
8秒前
踏实映天发布了新的文献求助10
8秒前
英俊的铭应助酷炫翠桃采纳,获得10
9秒前
辛辛发布了新的文献求助10
9秒前
月明完成签到,获得积分20
9秒前
9秒前
皮蛋_WH完成签到,获得积分10
9秒前
SYLH应助JingP采纳,获得20
10秒前
瘦瘦妖妖发布了新的文献求助10
10秒前
11秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974797
求助须知:如何正确求助?哪些是违规求助? 3519250
关于积分的说明 11197623
捐赠科研通 3255405
什么是DOI,文献DOI怎么找? 1797769
邀请新用户注册赠送积分活动 877156
科研通“疑难数据库(出版商)”最低求助积分说明 806202